Welcome to our dedicated page for Mustgrow Biologics news (Ticker: MGROF), a resource for investors and traders seeking the latest updates and insights on Mustgrow Biologics stock.
MustGrow Biologics Corp. (MGROF) generates frequent news and corporate updates related to its role in biological and regenerative agriculture. As a fully integrated provider of mustard-derived biocontrol and biofertility products, along with third-party crop nutrition solutions, the company issues news on product performance, commercialization progress, financing activities, and distribution partnerships.
Investors following MustGrow’s news can expect regular coverage of developments around its TerraSante™ organic biofertility product, including large-scale field trial results, registration status in U.S. states, and demand trends among U.S. commercial farming operations. The company also reports on TerraMG™, its mustard-based biopesticide platform, including registration efforts in Canada and the United States and collaborative work with partners such as Bayer AG in Europe, the Middle East, and Africa.
News releases also highlight MustGrow’s Canadian sales and distribution division, NexusBioAg, which handles third-party crop nutrition products and serves as a sales channel for the company’s proprietary technologies. Announcements may include new distribution agreements, such as the Canadian distribution of the RhizoSorb® phosphorus efficiency product, as well as commentary on seasonal sales patterns in the Canadian agriculture market.
In addition, MustGrow’s news flow includes financial and corporate updates such as quarterly operating results, private placements under the listed issuer financing exemption, lines of credit, share-based incentive grants, and outcomes of annual shareholder meetings. For investors and analysts, the MGROF news page on Stock Titan provides a consolidated view of these operational, financial, and strategic developments.
MustGrow (TSXV: MGRO / OTCQB: MGROF) announced results from a 2-year, ~100-acre Prairie field program showing its mustard-derived biocontrol TerraMG reduced Clubroot inoculum and improved canola root health and yields. Trials showed up to 95% spore reductions in 2024 and yield gains up to 7 bu/acre (≈19%). The company is pursuing registration with Health Canada's Pest Management Regulatory Agency and reports variable 2025 gains (1–2 bu/acre) in drier, lower-disease conditions.
MustGrow (OTCQB: MGROF / TSXV: MGRO) closed a non-brokered private placement of 4,000,000 units at CA$0.50 per unit for gross proceeds of CA$2.0 million. Each Unit includes one common share and one warrant exercisable at CA$0.70 for 60 months. Net proceeds will fund inventory production for TerraSante, agricultural inventory for NexusBioAg distribution, and working capital. Finder compensation included CA$105,000 cash and 210,000 finder warrants exercisable at CA$0.70 for 60 months. The issuance is subject to final TSXV approval and applicable statutory hold periods for finder warrants.
MustGrow (OTCQB: MGROF) announced a non-brokered private placement (the "LIFE Offering") of up to 4,000,000 Units at $0.50 per Unit to raise up to $2,000,000. Each Unit includes one common share and one warrant exercisable at $0.70 for 60 months. Net proceeds are intended for TerraSante inventory production, inventory for NexusBioAg distribution, and working capital. Closing is expected on or about January 22, 2026, subject to TSXV approval and other conditions. Eligible finders may receive up to 6% cash fees and Finder's Warrants representing up to 6% of Shares issued to introduced investors. Insider participation is anticipated and will be subject to TSXV hold periods and MI 61-101 exemptions.
MustGrow (OTCQB: MGROF) issued a CEO letter dated December 18, 2025 describing its 2025 transition from product development to commercialization. Key points: TerraSante saw accelerating U.S. demand with repeat orders after field trials; a Washington grower reported a 2 ton/acre potato yield gain and ~35% more A/B grades, implying ~US$5,000/acre added value versus ~US$180/acre product cost. MustGrow plans 2026 manufacturing scale‑ups with contract manufacturers to improve margins and is pursuing additional production partners and international registrations. TerraMG registration work continues in Canada and the U.S., and Bayer partnership progress in EMEA remains active.
MustGrow (OTCQB: MGROF) reported large-scale U.S. potato field results showing material yield, size and quality gains from its organic TerraSanteTM biofertility product.
Customer data in Washington showed an approximate 2 ton/acre yield increase and larger tuber size with fewer culls, which the farmer estimated as about a US$5,000 increase in value per acre at a product cost of US$180/acre. Small-plot trials also showed yield lifts vs untreated: +27.6% at 15 lbs/ac, +25.8% at 20 lbs/ac, and +39.2% at 50 lbs/ac. TerraSante is OMRI listed and registered for sale in CA, FL, AZ, ID, OR, WA. The company highlights soil-microbiome and nutrient-use benefits when used with grower programs.
MustGrow (OTCQB: MGROF) reported Q3-2025 operating and financial results for the three months ended September 30, 2025, announcing its first recorded quarterly sales since the prior-year period.
- Sales revenue: $0.8 million in Q3-2025 vs. no revenue in Q3-2024
- Gross profit: $180,555; gross margin 22.9% (up from 20.9% in Q2-2025)
- Cash and equivalents: $3.3 million as of September 30, 2025
- Inventory: $1.9 million as of September 30, 2025
The company noted Q3 is a seasonal shoulder period for Canadian agriculture and expects stronger retail demand in Q4-2025 and Q1-2026 as farmers buy crop inputs. Management cited margin improvement driven by higher-margin product sales through NexusBioAg and continues to allocate capital toward NexusBioAg and U.S. TerraSante biofertility sales.
MustGrow Biologics (OTCQB: MGROF) announced the grant of 1,660,315 deferred share units (DSUs) and restricted share units (RSUs) to directors, officers, and consultants, effective September 25, 2025. The grants were made under the company's Omnibus Equity Incentive Plan.
The DSUs will vest upon the holder's departure from their role at the company or its affiliates. Upon settlement, DSU holders will receive either one common share or an equivalent cash payment at the company's discretion.
MustGrow Biologics (OTCQB: MGROF) has secured a $2.0 million line of credit (LOC) from CIBC, guaranteed by Export Development Canada. The LOC carries an interest rate of prime rate plus 1.00% (current prime rate: 4.95%).
The funding will be used to produce TerraSante™, the company's organic mustard-derived biofertility product, to meet growing U.S. commercial farming demand. Additionally, the LOC will support working capital requirements for NexusBioAg, MustGrow's Canadian sales and distribution division.
MustGrow Biologics (OTCQB: MGROF) has completed several financial transactions to strengthen its capital structure. The company closed a non-brokered LIFE offering of approximately $2.1 million, issuing 3,059,731 units at $0.70 per unit. Each unit includes one common share and one warrant exercisable at $0.90 for 60 months.
Additionally, MustGrow repriced its January 2025 warrants from $1.90 to $0.90 per share and implemented a shares-for-debt settlement of $2.385 million in convertible debentures through the issuance of approximately 3.4 million shares at $0.70 per share. The proceeds will fund inventory production for TerraSante™ biofertility product and NexusBioAg distribution platform.
MustGrow Biologics (OTCQB: MGROF), a biological and regenerative agriculture solutions provider, reported strong Q2-2025 financial results. The company achieved revenue of $2.8 million, including $312,832 from TerraSante™ biofertility product sales in the U.S., compared to no revenue in Q2-2024.
The company improved its gross profit margin to 20.9% in Q2-2025, up from 14.3% in Q1-2025. TerraSante™ sales in Q2 tripled the entire 2024 sales volume, with inventory selling out due to growing demand. The company maintained a stable financial position with $1.8 million in cash and equivalents and $1.8 million in inventory as of June 30, 2025. The quarter resulted in a net loss of $1.1 million, or $0.02 per basic share.